Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT).

purposePOSEIDON (NCT03164616) was a randomized, open-label, multicenter phase III trial comparing first-line durvalumab with or without tremelimumab in combination with chemotherapy versus chemotherapy alone in patients with metastatic non-small cell lung cancer (NSCLC). Overall survival (OS) and progression-free survival were significantly increased in the tremelimumab plus durvalumab and chemotherapy arm. We conducted a post hoc analysis (TRIDENT) to identify patients who may receive greater OS benefit from the addition of tremelimumab to durvalumab and chemotherapy. EXPERIMENTAL

designThis analysis included clinical, genomic, and radiomic data from the POSEIDON trial (data cutoff March 12, 2021). Machine learning models leveraging multimodal data were trained to identify subpopulations of patients who benefit from the addition of tremelimumab to first-line durvalumab and chemotherapy.

resultsUsing clinical and genomic data, the model was able to predict treatment benefit from adding tremelimumab to first-line durvalumab and chemotherapy, with the top ranked 50% of patients with nonsquamous tumors achieving a hazard ratio of 0.56 (95% confidence interval, 0.33-0.97). EGFR wild type, FGFR3 wild type, CDKN2A wild type, KRAS mutations, and STK11 mutations were the factors most associated with higher OS benefit.

conclusionsBy utilizing machine learning models to analyze POSEIDON data, we yielded genetic signatures identifying patients with nonsquamous metastatic NSCLC who may derive greater OS benefit from the addition of tremelimumab to first-line durvalumab and chemotherapy. Such approaches could be used in the future to enhance precision in tailoring therapies for individual patients.